Although Jacob Becraft had two swings and two misses when he first tried to become an entrepreneur as a graduate student, the MIT Sandbox Innovation Fund Program allowed him to keep at it. This especially benefited cancer patients, as Becraft went on to co-found Strand Therapeutics: a $550-million firm whose programmable mRNA drug has shrunk tumors in patients who had exhausted all other treatment options. Stories like Becraft's took center stage at the recent 10-year anniversary celebration of the MIT Sandbox Innovation Fund Program, where student founders, alumni, mentors, and university leaders gathered to reflect on a decade of empowering student entrepreneurs. Speaking at the event, Becraft referred to Strand as "our third swing at the plate," explaining that the Sandbox model gave him "the freedom and ability to fail fast" ' letting previous venture ideas "blow up in our faces" before moving on. For Strand, Becraft says, MIT Sandbox helped him and his co-founder, Tasuku...
learn more
